Trial Profile
A Double-blind, Double-dummy, Multicenter Randomized Study Of The Efficacy And The Tolerability Of Valdecoxib 40mg Vs Rofecoxib 50mg In The Symptomatic Treatment Of Patients With Ankle Sprain
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Rofecoxib (Primary) ; Valdecoxib (Primary)
- Indications Ankle injuries
- Focus Therapeutic Use
- Sponsors Pfizer
- 06 Dec 2018 New trial record